Zymeworks (ZYME) Free Cash Flow (2021 - 2026)
Zymeworks recorded quarterly Free Cash Flow of -$45.8 million in Q1 2026, down 391.66% quarter-over-quarter from -$9.3 million in Q4 2025, and down 1238.53% year-over-year from $4.0 million in Q1 2025.
Zymeworks' Free Cash Flow history runs 6 years deep, the most recent figure standing at -$45.8 million for Q1 2026.
- In Q1 2026, Free Cash Flow fell 1238.53% year-over-year to -$45.8 million; the TTM figure through Mar 2026 stood at -$75.4 million (up 0.54% YoY), while the FY2025 annual figure was -$33.0 million, up 70.01% from the prior year.
- Free Cash Flow came in at -$45.8 million for Q1 2026 at Zymeworks, down from -$9.3 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $320.6 million in Q4 2022 to a low of -$83.6 million in Q1 2023.
- A 5-year average of -$10.2 million and a median of -$31.8 million in 2025 frame the typical range for Free Cash Flow.
- Across the five-year window, Free Cash Flow soared 679.9% in 2022 and plunged 1238.53% in 2026, its largest moves.
- Zymeworks' Free Cash Flow stood at $320.6 million in 2022, then plunged by 95.77% to $13.6 million in 2023, then slumped by 393.39% to -$39.8 million in 2024, then soared by 76.6% to -$9.3 million in 2025, then slumped by 391.66% to -$45.8 million in 2026.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$45.8 million, -$9.3 million, and -$31.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Zymeworks | 1.84 Bn | 1.47 Bn | - | -45.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -45.82 Mn |
| Mar 31, 2026 | -45.82 Mn |
| Dec 31, 2025 | -9.32 Mn |
| Dec 31, 2025 | -9.32 Mn |
| Sep 30, 2025 | -31.82 Mn |
| Sep 30, 2025 | -31.82 Mn |
| Jun 30, 2025 | 11.56 Mn |
| Jun 30, 2025 | 11.56 Mn |
| Mar 31, 2025 | -3.42 Mn |
| Mar 31, 2025 | -3.42 Mn |
| Dec 31, 2024 | -39.83 Mn |
| Dec 31, 2024 | -39.83 Mn |
| Sep 30, 2024 | -6.78 Mn |
| Sep 30, 2024 | -6.78 Mn |
| Jun 30, 2024 | -25.77 Mn |
| Jun 30, 2024 | -25.77 Mn |
| Mar 31, 2024 | -37.68 Mn |
| Mar 31, 2024 | -37.68 Mn |
| Dec 31, 2023 | 13.58 Mn |
| Dec 31, 2023 | 13.58 Mn |
| Sep 30, 2023 | -43.60 Mn |
| Sep 30, 2023 | -43.60 Mn |
| Jun 30, 2023 | -7.20 Mn |
| Jun 30, 2023 | -7.20 Mn |
| Mar 31, 2023 | -83.58 Mn |
| Mar 31, 2023 | -83.58 Mn |
| Dec 31, 2022 | 320.64 Mn |
| Dec 31, 2022 | 320.64 Mn |
| Sep 30, 2022 | -73.44 Mn |
| Sep 30, 2022 | -73.44 Mn |
| Jun 30, 2022 | -51.67 Mn |
| Jun 30, 2022 | -51.67 Mn |
| Mar 31, 2022 | -59.57 Mn |
| Mar 31, 2022 | -59.57 Mn |
| Dec 31, 2021 | -55.29 Mn |
| Dec 31, 2021 | -55.29 Mn |